Movement Alert｜Roivant Sciences Rises 11.1% in Regular Trading, Business Progress Updates Drive Positive Market Reaction Despite Revenue Miss

Market Focus05-20

On May 20, Roivant Sciences rose 11.1% in regular trading, trading at $30.54/share, with trading volume of approximately $35.74 million. The rally was driven by the company's disclosure of fiscal fourth-quarter and full-year financial results alongside business progress updates.

The company reported fiscal Q4 earnings per share from continuing operations of $0.28. Revenue came in at $2.52 million, missing the consensus estimate of $3.82 million. Despite the revenue shortfall, the simultaneous release of business development updates received a strongly positive market reaction, pushing shares higher from pre-market through regular trading hours.

Roivant Sciences is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines in inflammation and immunology. Its pipeline includes VTAMA for psoriasis and atopic dermatitis, batoclimab and IMVT-1402 targeting autoimmune indications, and RVT-3101 for ulcerative colitis and Crohn's disease. The company operates through its Vant model, building focused subsidiaries to accelerate transformative drug development.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193213945?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 21:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193213945","market":"us","top_or_hot":-1,"title":"Movement Alert｜Roivant Sciences Rises 11.1% in Regular Trading, Business Progress Updates Drive Positive Market Reaction Despite Revenue Miss","media":"Market Focus","content":"<p><p>On May 20, Roivant Sciences rose 11.1% in regular trading, trading at $30.54/share, with trading volume of approximately $35.74 million. The rally was driven by the company's disclosure of fiscal fourth-quarter and full-year financial results alongside business progress updates.</p><p>The company reported fiscal Q4 earnings per share from continuing operations of $0.28. Revenue came in at $2.52 million, missing the consensus estimate of $3.82 million. Despite the revenue shortfall, the simultaneous release of business development updates received a strongly positive market reaction, pushing shares higher from pre-market through regular trading hours.</p><p>Roivant Sciences is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines in inflammation and immunology. Its pipeline includes VTAMA for psoriasis and atopic dermatitis, batoclimab and IMVT-1402 targeting autoimmune indications, and RVT-3101 for ulcerative colitis and Crohn's disease. The company operates through its Vant model, building focused subsidiaries to accelerate transformative drug development.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Roivant Sciences Rises 11.1% in Regular Trading, Business Progress Updates Drive Positive Market Reaction Despite Revenue Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Roivant Sciences Rises 11.1% in Regular Trading, Business Progress Updates Drive Positive Market Reaction Despite Revenue Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-20 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 20, Roivant Sciences rose 11.1% in regular trading, trading at $30.54/share, with trading volume of approximately $35.74 million. The rally was driven by the company's disclosure of fiscal fourth-quarter and full-year financial results alongside business progress updates.</p><p>The company reported fiscal Q4 earnings per share from continuing operations of $0.28. Revenue came in at $2.52 million, missing the consensus estimate of $3.82 million. Despite the revenue shortfall, the simultaneous release of business development updates received a strongly positive market reaction, pushing shares higher from pre-market through regular trading hours.</p><p>Roivant Sciences is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines in inflammation and immunology. Its pipeline includes VTAMA for psoriasis and atopic dermatitis, batoclimab and IMVT-1402 targeting autoimmune indications, and RVT-3101 for ulcerative colitis and Crohn's disease. The company operates through its Vant model, building focused subsidiaries to accelerate transformative drug development.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROIV","symbol_name":"Roivant Sciences Ltd.","start_time":0,"source_url":"","article_id":"1193213945","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193213945","pubTimestamp":1779284441,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 20, Roivant Sciences rose 11.1% in regular trading, trading at $30.54/share, with trading volume of approximately $35.74 million. The rally was driven by the company's disclosure of fiscal...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ROIV":"Roivant Sciences Ltd."},"translate_title":"动向警报|Roivant Sciences常规交易上涨11.1%，尽管营收未达预期，业务进展更新仍推动市场积极反应","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":1},"content_text":"On May 20, Roivant Sciences rose 11.1% in regular trading, trading at $30.54/share, with trading volume of approximately $35.74 million. The rally was driven by the company's disclosure of fiscal fourth-quarter and full-year financial results alongside business progress updates.The company reported fiscal Q4 earnings per share from continuing operations of $0.28. Revenue came in at $2.52 million, missing the consensus estimate of $3.82 million. Despite the revenue shortfall, the simultaneous release of business development updates received a strongly positive market reaction, pushing shares higher from pre-market through regular trading hours.Roivant Sciences is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines in inflammation and immunology. Its pipeline includes VTAMA for psoriasis and atopic dermatitis, batoclimab and IMVT-1402 targeting autoimmune indications, and RVT-3101 for ulcerative colitis and Crohn's disease. The company operates through its Vant model, building focused subsidiaries to accelerate transformative drug development.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193213945","isCrawlerRequest":true}